Key points are not available for this paper at this time.
Neoadjuvant trials introduce new drugs preoperatively in patients with localized breast cancer, using the rate of pathological complete response as the primary end point. The FDA has issued guidance for using this end point in applying for accelerated drug approval.
Prowell et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: